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Disorders of immune dysregulation following heart transplantation in children have been
reported; however, the management of such disorders remains uncertain and challenging.
In this case report, we describe a clinical course of a child with severe autoimmune
enteropathy after a heart transplant in infancy and detail a treatment approach with
abatacept and alemtuzumab. A 21-month-old girl with a medical history of congenital
dilated cardiomyopathy and heart transplantation at 2 months was evaluated for chronic
hematochezia. The patient underwent an extensive workup, including endoscopic biopsy
which showed crypt apoptosis, similar to that seen with graft-versus-host disease (GVHD).
Results of her immune workup were consistent with status post-thymectomy but also
demonstrated evidence of immune dysregulation. Speciﬁcally, her immune phenotype at
diagnosis demonstrated T-cell lymphopenia, restricted TCR repertoire and skewing of T-cell
compartment toward memory phenotype, increase in serum soluble ILR2a, and
hypergammaglobulinemia. In the absence of response to more standard immune
modulation, the patient was treated with CTLA4-Ig (abatacept), followed by a
combination of abatacept and a JAK inhibitor and, ﬁnally, a combination of abatacept
and alemtuzumab. Following therapy with alemtuzumab, the patient achieved remission for
the ﬁrst time in her life. Her clinical course was complicated by a relapse after 6 months
which again readily responded to alemtuzumab. Ultimately, despite these remissions, the
patient suffered an additional relapse. This case highlights the challenges of neonatal
thymectomy and adds new insights into the pathogenesis, diagnosis, and management of
severe autoimmune enteropathy in pediatric heart transplant recipients.
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autoimmune disorders in pediatric heart transplant recipients
is challenging. Here, we describe a clinical course of a child who
was diagnosed with severe autoimmune enteropathy after a heart
transplant in infancy and treated with a combination of
abatacept and alemtuzumab.

INTRODUCTION
Heart transplantation in infancy represents a complex challenge
to the developing immune system. During the procedure, the
thymus is frequently removed to allow for sternotomy and
cannulation of the great vessels. It is now appreciated that
thymectomy leaves a characteristic imprint on the immune
system, similar to that observed in immunosenescence, and the
impact of thymectomy performed in the neonatal period is even
more profound (1–3). In addition, the use of immunosuppressive
drugs required to prevent rejection, such as antithymocyte
globulin and tacrolimus, further depletes the developing T-cell
compartment present at the time of treatment. The interplay of
these factors creates a unique immune phenotype in children
who undergo cardiac transplantation in infancy, which has been
characterized in a limited number of studies. Notably, despite
peripheral proliferation of residual T cells and restoration of
near-normal numbers of CD3+ T cells in the blood, the
phenotype of such T cells is signiﬁcantly altered compared
with healthy children. In the absence of normal thymic output
and negative selection in the thymus, children who have
undergone thymectomy have restricted T-cell receptor (TCR)
diversity and skewing of T-cell phenotype to memory
(CD45RO+) cells, which can sometimes lead to impaired Tcell-dependent antibody response to pathogens and
overproduction of antibodies to self-antigens (4, 5).
Increased risk of de-novo autoimmune disorders has been
reported in recipients of solid organs and is generally thought to
be related to immune dysregulation from immunosuppressive
drugs. Marcus et al. reported the largest group of pediatric solid
organ recipients to date, of which 103 patients were heart
transplant recipients. In this study, autoimmune disorders,
most commonly autoimmune cytopenias, inﬂammatory bowel
disease (IBD), and IBD-like, were observed in pediatric heart
recipients with a prevalence of 9.7% (3). It remains a question,
however, whether immune-mediated disorders following heart
transplantation share the same pathophysiology (and therefore
amenable to the same treatments) with those following other
solid organ transplantation, considering the unique immune
phenotype of these patients. Management of refractory

CASE DESCRIPTION
A 21-month-old girl was evaluated for chronic diarrhea. Her
medical history was signiﬁcant for dilated cardiomyopathy
associated with a pathogenic variant in MYBPC3 for which she
underwent ABO-compatible, complement-dependent cytotoxicity
crossmatch negative orthotopic heart transplantation at the age of
2 months. Her diarrhea started approximately 6 months after
transplantation as intermittent non-bloody loose stools, which
gradually progressed to persistent hematochezia which required
daily transfusions of red blood cells (RBCs). Due to her
gastrointestinal (GI) illness and feeding intolerance, at 1 year of
age, she was only at the 26th percentile for weight and 13th
percentile for height and dependent on gastrostomy tube feedings.
Her physical exam revealed a small child with no skin rash,
lymphadenopathy, or organomegaly. Her thymic function prior
to cardiac transplant and thymectomy is unknown, as routine
neonatal screening for severe combined immunodeﬁciency
(SCID) was not yet in place when she was born. At 5 months of
age, she had a repeat newborn screen that demonstrated absent Tcell receptor excision circles (TRECs). Upon referral to the
immunology consulting service, clinical assessment of her Tlymphocyte compartment at 21 months showed low recent
thymic emigrants (CD4RTE, % of CD3 + CD4 + that are
CD45RA+CD31+) (Table 1). CD45RA/RO analysis of CD4 cells
demonstrated a signiﬁcant skewing to memory phenotype.
TCRVb spectratyping demonstrated an altered T-cell repertoire
with 15 oligoclonal families. These ﬁndings are consistent with
thymectomy including T-cell lymphopenia, T-cell repertoire
restriction, and skewing of T-cell population to memory
phenotype. Other pertinent ﬁndings included elevated serum
IIL2Ra, indicative of a strong antigen stimulation of T cells, and

TABLE 1 | Immunologic evaluation of the patient between 5 and 36 months of age.
Age:

5 months

TREC, cycle threshold (CT)
TREC, copies/106 CD3+ T cells
CD3, cells/ml
CD4, cells/ml
CD8, cells/ml
CD19, cells/ml
CD56/16, cells/ml
CD4RTE, % of CD4+ T cells
CD45RA, % of CD4+ T cells
CD45RO, % of CD4+ T cells
TCRVb repertoire
IgG, mg/dl
Soluble IL2Ra, IU/ml

45 (absent)

13 months

274
64
120
592
1,065

21 months

Undetectable
396
122
122
822
183
0.8
2
98
Predominantly oligoclonal and polyclonal non-Gaussian
1,833
1,280

36 months

<55
<35
<45
<25
>2,000

1,382

Ref range
<36
>6,794
2,100–6,200
1,300–3,400
620–2,000
720–2,600
180–920
25.8–68
63–91
7–20
Polyclonal Gaussian
345–1,213
45–1,105

CD4RTE, CD4 T-cell recent thymic emigrants (percentage of CD3+CD4+ cells that are CD31+ CD45RA+cells).
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In an effort to promote regulatory T-cell function and suppress
autoreactive effector T cells, her initial immunosuppressive therapy
with tacrolimus was changed to everolimus, an mTOR inhibitor.
However, she continued to have recurrent gastrointestinal bleeding,
ultimately requiring a subtotal colectomy, proctectomy, and end
ileostomy. A biopsy taken from the large bowel at the time of the
laparotomy again demonstrated features of acute GVHD, consistent
with T-cell-mediated enteropathy (Figure 1). Despite continued
treatment with everolimus and steroids, GI bleeding from ulceration
in the small intestine persisted. We therefore approached treatment
similar to that of patients with allogeneic GVHD and initiated
abatacept therapy (10 mg/kg at induction dosing interval on days 0,
6, 15, and 30). This was quickly followed by a combination of
abatacept with ruxolitinib (5 mg twice daily) and, ﬁnally, a
combination of abatacept with alemtuzumab (0.2 mg/kg daily × 5
days) (Figure 2). Following alemtuzumab, she had a clinical
response with cessation of gastrointestinal bleeding accompanied
by normalization of the level of soluble IL2Ra (920 IU/ml).
Abatacept was continued as maintenance therapy at 50 mg/week
subcutaneously. In addition, she received weekly subcutaneous
immunoglobulin infusions for secondary hypogammaglobinemia.
The patient was discharged after 160 days in the hospital in stable
condition on weekly abatacept, antimicrobial prophylaxis, and
weekly subcutaneous immunoglobulin.
After almost 4 months of sustained remission on outpatient
therapy, which was the longest period she was not hospitalized in
her life, abatacept was spaced out to every 14 days. Unfortunately,
she developed hematemesis and was readmitted to the hospital.
Endoscopic biopsy of the ileum revealed crypt apoptosis and
gland dropout with minimal inﬂammation, similar to changes
observed at the time of her laparoscopy and consistent with acute
GVHD-like pathology. Her soluble IL2Ra increased to 1,382 IU/
ml, indicating T-cell activation. Other causes of GI bleeding were
excluded. At this point, 8 months post-treatment with
alemtuzumab, her peripheral blood ﬂow cytometry revealed
undetectable levels of T and B cells, indicating that her

hypergammaglobulinemia, thought to be due to overactivation of
B cells in the absence of T-cell inhibitory signals. Genetic testing
for known causes of SCID and combined immunodeﬁciencies was
negative (clinical 207 gene panel). An extensive infectious workup
was negative with the exception of persistent human herpesvirus 6
(HHV-6) viremia, which had been previously treated with
ganciclovir but did not improve the diarrhea. Endoscopic biopsy
of the patient’s colon showed crypt apoptosis, with a pathologic
appearance of graft-versus-host disease (GVHD) after allogeneic
hematopoietic stem cell transplantation (HSCT). A biopsy of her
heart showed no evidence of graft rejection or GVHD.
The patient’s immune phenotype was consistent with a
history of thymectomy due to cardiac transplant, but was also
similar to that seen in Omenn syndrome, an immune
dysregulation syndrome in patients with “leaky” SCID
characterized by the presence of autoreactive oligoclonal T
cells (6). In Omenn syndrome, autoreactive T cells inﬁltrate
the skin, GI tract, and other organs leading to erythroderma,
chronic diarrhea, and failure to thrive (7). A similar
phenomenon of autoreactive T cells has been recognized in
some autologous HSCT recipients (8, 9). Theoretically, patients
undergoing autologous HCST should be exempt from GVHD,
since there is no HLA disparity between infused stem cells and
the recipient (9). Interestingly, pathology similar to allogeneic
GVHD is present in ~10% of autologous HCST recipients,
termed “autologous GVHD” or “auto-GVHD,” but is typically
mild and limited to the skin (8). However, a more severe
presentation with gut involvement has been described,
including patients with persistent diarrhea and GVHD-like
pathology (9). Based on the immune phenotype and
gastrointestinal tract pathology in our patient and the
previously described syndromes, we hypothesized that the
patient’s enteropathy represented autologous GVHD
enteropathy due to T-cell dysregulation.
Her enteropathy was initially treated with methylprednisolone;
however, she continued to have GI bleeding despite this therapy.

A

B

FIGURE 1 | Autologous graft-versus-host disease in the colon. Fragments of colon tissue from the patient demonstrating diffuse subtotal loss of mucosa with
marked epithelial apoptosis (green arrows) and intermittent ulcers, consistent with severe autologous graft-versus-host disease. (A) ×40 and (B) ×400 magniﬁcation.
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FIGURE 2 | Treatment of enteropathy. The table displays the time course, details, and outcomes of treatment of enteropathy from 28 to 38 months.

a month after discharge, she represented to the hospital with
feeding intolerance and was diagnosed with acute pancreatitis,
hepatitis, and gastroenteritis. The option of allogeneic HCST was
discussed, but deemed very high risk, considering the patient’s
clinical status, her history of cardiac transplant, and the
uncertainty of T-cell reconstitution with athymia. Thymic tissue
transplantation was also discussed, but is not currently clinically
available for this indication. Despite an extensive workup, the
cause of her acute worsening remained uncertain but was thought

peripheral T- and B-cell compartments did not reconstitute. Her
NK cells, by contrast, had recovered and were increased to more
than 2,000 cells/ml. We hypothesized that the recurrence of GI
bleeding was caused by autoreactive T cells already recruited to
the site of self-antigen presentation in the small intestine.
Therefore, pulse therapy with alemtuzumab was reinstated at
0.2 mg/kg every 48 h for 4 doses which again resulted in the
resolution of GI bleeding. The patient was discharged on
maintenance therapy with biweekly abatacept. However, within
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enteropathy, considering its half-life of approximately 14 days.
We speculate that the initial success with abatacept and
alemtuzumab was counteracted by complications associated
with secondary immune deﬁciency and a relapsing nature of
the pathology.
This case illustrates the impact of neonatal heart
transplantation and thymectomy on the developing immune
system, alerts the physicians to consider autoimmunity as a
potential cause of enteropathy in pediatric heart transplant
recipients, and describes the approach to the management of
severe autoimmune enteropathy with abatacept
and alemtuzumab.

to be multifactorial, including possible HHV-6 infection and
drug-induced toxicity. Her condition progressively deteriorated
as she developed pancytopenia, ulcerations at the ostomy site, and
GI bleeding. At that point, the decision was made to transition her
care to comfort measures, and the patient succumbed to
her illness.

DISCUSSION
Autoimmune enteropathy has been described as a component of
inborn errors of immunity such as immunodysregulation
polyendocrinopathy enteropathy X-linked (IPEX) and other
disorders with loss of T-cell tolerance, as well as in association
with other non-syndromic immune-mediated conditions and as
an isolated disorder (10). Autoimmune enteropathy is a wellrecognized complication of GVHD in patients following
allogeneic HSCT; however, recipients of autologous transplants
can also have auto-GVHD and autoimmune enteropathy (8, 9).
Recent evidence suggests that in comparison to allogeneic
GVHD driven by the disparity in donor and recipient HLA,
the mechanism underlying autologous GVHD may be due to
impaired reconstitution of the thymic medulla resulting in the
loss of T-cell tolerance (11, 12).
Treatment of steroid-refractory cases of autoimmune
enteropathy can be challenging, and multiple immune
modulatory drugs have been tried with varied success. When
refractory to medical therapies, HCST has been used to reset the
immune system (13, 14). Management of immune dysregulation
in transplant patients is further complicated due to the inherent
requirement for immunosuppressive medications. Reports on
autoimmune enteropathy and its management and outcomes in
pediatric heart transplant recipients are scarce (15). Our
treatment approach to this case was based on the ﬁndings of
acute GVHD-like pathology and leaky SCID-like immune
phenotype of the patient. We observed a favorable and
reproducible clinical response to a combination of
alemtuzumab and abatacept. The prompt clinical response to
this immune modulatory therapy substantiated our hypothesis
that immune dysregulation was indeed an underlying
pathophysiology of enteropathy. It remains unclear why the
response to abatacept and alemtuzumab did not translate into
sustained remission. It is less likely that changing the abatacept
dose to every 2 weeks precipitated the worsening of autoimmune
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